Rachel Bhatt

Rachel Bhatt studies resistance mechanisms to CDK4/6 inhibitors in hormone receptor-positive breast cancer. Her translational research has identified tumor cell-intrinsic mechanisms including RB1 loss, CCND1 amplification, and CDK6 upregulation as drivers of acquired resistance to palbociclib and ribociclib. She investigates potential therapeutic strategies to overcome these resistance mechanisms through drug combinations and sequential treatment approaches. Her laboratory work informs the design of clinical trials for patients progressing on CDK4/6 inhibitor-based therapy.